New Recurrence clinical trials: 482 posted since Nov 2024

Name: New Recurrence clinical trials
Creator: SpecStream
License: https://creativecommons.org/licenses/by/4.0/

The full list. New Recurrence clinical trials: 482 rows for $24.10, first posted on ClinicalTrials.gov from November 12, 2024 to November 9, 2026. The list gains about 21 rows a month. The new rows come each week by email, $19 a month.

Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, enrollment type, location countries and 5 more), which open on your screen as soon as the payment clears and come by email. The weekly rows run until you cancel, from the link in each delivery. The rows on this page are a sample.

For agents and scripts: this list is ordered at https://specstream.ai/data/clinical-trials/condition/recurrence, and every list with its row count and price is at https://specstream.ai/data/lists.json.

Updated November 9, 2026. Source: ClinicalTrials.gov API v2 (U.S. National Library of Medicine).

482 clinical studies in recurrence were first posted on ClinicalTrials.gov from November 12, 2024 to November 9, 2026; 139 have an industry sponsor and 402 are recruiting or about to. The newest, NCT07926464, was posted on November 9, 2026: Laparoscopic Transabdominal Preperitoneal Technique in Repair of Recurrent Inguinal Hernia (Port Said University hospital).

The request: Every new Recurrence clinical trial on ClinicalTrials.gov, with the sponsor, phase, sites and the listed contact. $10 of credit on sign-up, no card.

Get new trials like these Watch a sponsor

SpecStream is the live web data engine for teams and agents. It reads every new study on ClinicalTrials.gov each morning, and this page is that reading. Ask for the conditions, phases or countries you follow and each new trial arrives in your sheet, CRM, Slack or agent with the sponsor, the sites and the listed contact.

482New trials
139Industry sponsored
402Recruiting or not yet
November 9, 2026Latest posted

Newest trials

The newest 100 of 482, each linked to its record. The full list holds every one with the sponsor class, interventions, start date and the central contact as the record prints it.

First posted	NCT ID	Title	Sponsor	Phase	Status	Conditions	Enrollment	Countries	Source
November 9, 2026	NCT07926464	Laparoscopic Transabdominal Preperitoneal Technique in Repair of Recurrent Inguinal Hernia	Port Said University hospital	Not applicable	Completed	Laparoscopic, Transabdominal Preperitoneal, Repair, Recurrent, Inguinal Hernia	31	Egypt	clinicaltrials.gov
November 6, 2026	NCT07923071	A Study to Assess the Pharmacokinetics and Safety of Revumenib in Participants With Advanced Cancer and Hepatic or Renal Impairment	Syndax Pharmaceuticals	Phase 1	Not yet recruiting	Relapsed/Refractory (R/R) Hematologic Malignancies, Acute Leukemia, Refractory Leukemia, Relapsed Leukemia	18		clinicaltrials.gov
November 6, 2026	NCT07920796	Thiotepa + TBI + Fludarabine + Etoposide for Allo-HSCT in Patients With R/R or High-risk Acute Leukemia	Guangdong Second Provincial General Hospital	Phase 2	Enrolling by invitation	Acute Leukemia, High Risk, Acute Leukemia Refractory, Acute Leukemia, Relapsed	50	China	clinicaltrials.gov
November 3, 2026	NCT07913594	Zilovertamab Vedotin and Lenalidomide (ZiVLen) Therapy for Relapsed/Refractory Peripheral T-Cell Lymphoma	Olivia Newton-John Cancer Research Institute	Phase 2	Not yet recruiting	Peripheral T-Cell Lymphoma Refractory	25	Australia	clinicaltrials.gov
November 2, 2026	NCT07910708	GN001 for Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and B-Cell Acute Lymphoblastic Leukemia	Department of Hematology,Rheumatology and Immunology,Pu'er People's Hospital	Phase 1	Recruiting	Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma, Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia	42	China	clinicaltrials.gov
November 2, 2026	NCT07909031	CR-002 in Adult Participants With Locally Advanced or Metastatic Solid Tumors	Crescent Biopharma, Inc.	Phase 1/2	Recruiting	Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Gastric/GEJ, Biliary Tract Cancer (BTC)...	219	United States	clinicaltrials.gov
October 29, 2026	NCT07905664	Better Care Closer to Home: Enhancing Primary and Community Care	Universidad Complutense de Madrid	Not applicable	Not yet recruiting	Diabetic Foot Disease, Recurrence	84	Canada, Denmark, Spain	clinicaltrials.gov
October 28, 2026	NCT07901803	Aspirin and PAClitaxel in Head & Neck Squamous Cell Carcinoma	Washington University School of Medicine	Phase 2	Not yet recruiting	Head and Neck (HNSCC), Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Head and Neck...	40	United States	clinicaltrials.gov
October 27, 2026	NCT07899632	A Study of MDSY-1240, a STAT3 Degrader, for the Treatment of Hematologic Malignancies and Advanced Solid Tumors	Medsyn Biopharma, LLC	Phase 1/2	Not yet recruiting	Triple-Negative Breast Cancer (TNBC), Gastric Cancer (GC), Gastric Cancer Adenocarcinoma Metastatic, Ovarian Cancer...	75		clinicaltrials.gov
October 27, 2026	NCT07898436	Menin Inhibitors in Pediatric Relapsed or Refractory Acute Leukemia	University Hospital, Strasbourg, France	Observational	Recruiting	Acute Leukemia, Relapsed or Refractory Pediatric Leukemia, KMT2A-rearranged, NUP98-rearranged, or NPM1-mutated...	10	France	clinicaltrials.gov
October 27, 2026	NCT07897136	CLL-1/CD70 Dual-Target CAR-T Cell Therapy for Acute Myeloid Leukemia	Liping Dou	Phase 1	Not yet recruiting	Acute Myeloid Leukemia (AML), Relapsed/Refractory Acute Myeloid Leukemia	12	China	clinicaltrials.gov
October 26, 2026	NCT07896278	Onlay vs. Sublay Mesh Hernioplasty for Primary Ventral Hernia	Provincial Headquarter Teaching Hospital Gilgit	Not applicable	Completed	Ventral Hernia Repair, Hernia Abdominal Wall	76	Pakistan	clinicaltrials.gov
October 22, 2026	NCT07890025	CD19 CAR-T Cell Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: A Phase I/II Study	Hospital Universitario Dr. Jose E. Gonzalez	Phase 1/2	Not yet recruiting	Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia	30	Mexico	clinicaltrials.gov
October 20, 2026	NCT07883941	Phase I Safety Clinical Trial of Anti-CD19 CAR-T Therapy COL01 for the Treatment of Adults With Relapsed or Refractory B-cell Lymphoid...	GUSTAVO SALGUERO	Phase 1	Not yet recruiting	Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia, Lymphoid Malignancies, Diffuse Large B Cell Lymphoma...	12		clinicaltrials.gov
October 20, 2026	NCT07883135	Bispecific Antibody-Based Holding/Bridging Therapy Before CAR-T in Aggressive B-Cell Lymphomas	National Research Center for Hematology, Russia	Phase 2	Recruiting	Aggressive B-cell Non-Hodgkin Lymphoma (aNHL), Relapsed or Refractory B-cell Lymphoma	40	Russia	clinicaltrials.gov
October 15, 2026	NCT07874737	Mitoxantrone Hydrochloride Liposome Combined With Cladribine And Sotorasib For Relapsed Refractory Acute Myeloid Leukemia	The Affiliated People's Hospital of Ningbo University	Phase 2	Not yet recruiting	Relapsed and Refractory Acute Myeloid Leukemia (RR-AML)	20		clinicaltrials.gov
October 13, 2026	NCT07871877	Medically Supervised Ibogaine With 12-Month Digital Recovery Support for Opioid Use Disorder	Clive Michelsen	Phase 1/2	Not yet recruiting	Opioid Use Disorder, Opioid Withdrawal, Substance Use Disorders	60	United States	clinicaltrials.gov
October 13, 2026	NCT07870746	Phase 2a Study to Assess Safety and Efficacy of Two 177Lu-TLX250 Dosing Regimens in Advanced Relapsed or Recurrent ccRCC	Telix Pharmaceuticals (Innovations) Pty Limited	Phase 2	Not yet recruiting	ccRCC, Renal Cell Carcinoma (Kidney Cancer), Renal Cell Carcinoma (RCC), Renal Cell Cancer Metastatic, Renal Cell...	40	United States	clinicaltrials.gov
October 8, 2026	NCT07865130	Study of CDK8 Inhibitor RVU120 in Combination With Everolimus in Children With Recurrent or Progressive Group 3 or 4 Medulloblastoma	Bożenna Dembowska Bagińska	Phase 1	Not yet recruiting	Medulloblastoma Recurrent, Medulloblastoma	48	Poland	clinicaltrials.gov
October 7, 2026	NCT07862946	Inotuzumab as Post-Trasplantation Therapy for Adult High-risk B-cell Precursor Acute Lymphoblastic Leukemia	PETHEMA Foundation	Phase 2	Not yet recruiting	Acute Lymphobkastic Leukemia, Adult	30	Spain	clinicaltrials.gov
October 6, 2026	NCT07860177	Management of Non Emergency Adhesive Small Bowel Obstruction:	Azienda Sanitaria di Firenze	Observational	Enrolling by invitation	SBO - Small Bowel Obstruction	690	Italy	clinicaltrials.gov
October 5, 2026	NCT07859059	Metronomic Temozolomide With Dexbrompheniramine for Recurrent High-Grade Glioma/Glioblastoma	University of Nebraska	Phase 1/2	Not yet recruiting	High Grade Glioma, Glioblastoma, Gliosarcoma	41	United States	clinicaltrials.gov
October 1, 2026	NCT07853378	Incidence and Predictors of Early Clinical Relapse Within Six Months After Thymectomy in Patients With Myasthenia Gravis	Assiut University	Observational	Not yet recruiting	Myasthenia Gravis, Thymoma	30		clinicaltrials.gov
October 1, 2026	NCT07852377	Immunomonitoring and Predictive Biomarkers After CAR-T Cell Therapy in B-Cell Lymphoma and Multiple Myeloma	Centre Henri Becquerel	Not applicable	Not yet recruiting	B Cell Lymphoma, Multiple Mieloma	45	France	clinicaltrials.gov
September 29, 2026	NCT07847957	Roginolisib Plus Obinutuzumab + Venetoclax in R/R CLL	Dana-Farber Cancer Institute	Phase 1/2	Not yet recruiting	Chronic Lymphocytic Leukemia (CLL), Refractory Chronic Lymphocytic Leukemia	40	United States	clinicaltrials.gov
September 25, 2026	NCT07842445	Phase 1a/1b Clinical Trials to Evaluate the Safety and Preliminary Efficacy of GNTbm-38.	Great Novel Therapeutics Biotech & Medicals Corporation	Phase 1	Not yet recruiting	Solid Tumor (Phase I), Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)	70		clinicaltrials.gov
September 25, 2026	NCT07841002	CLL-1-Targeted In Vivo CAR-T Cell Immunotherapy for Relapsed/Refractory Acute Myeloid Leukemia	Liping Dou	Phase 1	Not yet recruiting	Relapsed/Refractory Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia (AML)	12	China	clinicaltrials.gov
September 25, 2026	NCT07840456	Safety and Efficacy of Ruxolitinib in Patients With HNSCC and High NLR Treated With Pembrolizumab - The Phase 2 InflammaSTOP Trial	University Hospital, Basel, Switzerland	Phase 2	Not yet recruiting	Carcinoma, Squamous Cell of Head and Neck HNSCC	66	Germany, Switzerland	clinicaltrials.gov
September 24, 2026	NCT07840092	Biomarker Validation for Treatment Efficacy and Recurrence Prediction in Hepatocellular Carcinoma	Tianjin Medical University Cancer Institute and Hospital	Observational	Recruiting	Hepatocellular Carcinoma (HCC)	500	China	clinicaltrials.gov
September 24, 2026	NCT07839767	Treatment Selection by 3D Bioprinting Liver Model to Prevent Liver Cancer Recurrence	The University of Hong Kong	Observational	Recruiting	HCC - Hepatocellular Carcinoma	20	Hong Kong	clinicaltrials.gov
September 24, 2026	NCT07838207	Prognosis and Therapeutic Implications in Molecular High-Risk Non-Myoinvasive Endometrial Cancer	Hospital Universitari Vall d'Hebron Research Institute	Observational	Recruiting	Endometrial Cancer, Endometrial Carcinoma (EC), p53abn	350	Spain	clinicaltrials.gov
September 16, 2026	NCT07822646	A Phase 3 Study of Manganese-primed Immunochemotherapy in Patients With Advanced Ovarian Cancer	Chinese PLA General Hospital	Phase 3	Recruiting	Ovarian Cancer	120	China	clinicaltrials.gov
September 15, 2026	NCT07819591	Paclitaxel Polymeric Micelles Plus Ivonescimab in Recurrent or Refractory SCLC	Shaodong Hong	Phase 2	Not yet recruiting	SCLC, Recurrent	47	China	clinicaltrials.gov
September 8, 2026	NCT07807293	Radioguided Salvage Pelvic Node Dissection in Oligometastatic Prostate Cancer - SALVAGE	University of British Columbia	Phase 2	Not yet recruiting	Prostate Cancer, Oligometastatic	62		clinicaltrials.gov
September 8, 2026	NCT07805915	Prospective One-Year Evaluation of the Safety and Effectiveness of an Investigator-Developed Rectus Abdominis Plication Technique in...	Research Inc	Not applicable	Recruiting	Diastasis Recti Abdominis, Abdominal Wall Laxity	100	Colombia	clinicaltrials.gov
September 4, 2026	NCT07804875	Symptom Trajectory Approaches to Research	University of Wisconsin, Madison	Observational	Not yet recruiting	Advanced Cancer, Metastatic Disease, Cancer Treatment, Progressive Disease, Recurrent Cancer	228	United States	clinicaltrials.gov
September 1, 2026	NCT07798479	Age and Bladder Cancer Outcomes After BCG Treatment: A Multicenter Study	Insel Gruppe AG, University Hospital Bern	Observational	Completed	Bladder Cancer, NMIBC	64		clinicaltrials.gov
September 1, 2026	NCT07797153	JSKN033 Versus Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Cancer	Jiangsu Alphamab Biopharmaceuticals Co., Ltd	Phase 3	Not yet recruiting	Recurrent or Metastatic Cervical Cancer	368	China	clinicaltrials.gov
September 1, 2026	NCT07796373	Nemtabrutinib for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Leukemia (SLL) Refractory to Covalent Bruton Tyrosine Kinase...	National Heart, Lung, and Blood Institute (NHLBI)	Phase 2	Not yet recruiting	Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia	32	United States	clinicaltrials.gov
August 31, 2026	NCT07793994	Pedi-STAR: Surface Target Antibody-drug Conjugate (ADC) Antigen Expression in Relapsed/Refractory Pediatric Solid and CNS Tumors	Dana-Farber Cancer Institute	Not applicable	Not yet recruiting	CNS Tumor, Solid Tumor, Relapsed Cancer, Refractory Cancer, Pediatric Cancer	130	United States	clinicaltrials.gov
August 28, 2026	NCT07791745	A Clinical Trial Comparing the Efficacy and Safety of Anyouping® and Platinum-based Chemotherapy With or Without Enlituo® in Advanced...	Taizhou Mabtech Pharmaceutical Co.,Ltd	Phase 2/3	Recruiting	Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M)	362	China	clinicaltrials.gov
August 28, 2026	NCT07791498	Teclistamab In Waldenstrom's Macroglobulinemia	Massachusetts General Hospital	Phase 2	Not yet recruiting	Waldenstrom's Macroglobulinemia	24	United States	clinicaltrials.gov
August 27, 2026	NCT07790380	FH-006 Versus Investigator's Choice of Chemotherapy in Patients With Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell...	Jiangsu HengRui Medicine Co., Ltd.	Phase 3	Recruiting	Locally Advanced, Recurrent or Metastatic ESCC Patients Who Have Failed Prior PD-1/PD-L1 Inhibitors Combined With...	480	China	clinicaltrials.gov
August 27, 2026	NCT07788976	Mandibular Medial Osteotomy Modifications and Postoperative Stability	Bezmialem Vakif University	Not applicable	Recruiting	Orthognathic Surgical Procedures	34	Turkey (Türkiye)	clinicaltrials.gov
August 26, 2026	NCT07788118	A Phase Ib/II Exploratory Clinical Trial of Memory-Enhanced 7×19-THEMIS CAR-T Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma	Second Affiliated Hospital, Zhejiang University, School of Medicine	Phase 1/2	Recruiting	Relapsed/Refractory Large B-cell Lymphoma (LBCL), Diffuse Large B-Cell Lymphoma (DLBCL), Primary Mediastinal Large...	70	China	clinicaltrials.gov
August 26, 2026	NCT07786922	A Study of Avatrombopag in Adults With Aplastic Anemia Who Did Not Respond to, Cannot Receive, or Had Return of Disease After Standard...	Swedish Orphan Biovitrum	Phase 2/3	Not yet recruiting	Aplastic Anemia	26		clinicaltrials.gov
August 25, 2026	NCT07784101	A Phase 3 Study to Compare the Efficacy of ICP-248 in Combination With Orelabrutinib Versus Pirtobrutinib in Participants With Relapsed or...	Beijing InnoCare Pharma Tech Co., Ltd.	Phase 3	Not yet recruiting	Relapsed or Refractory Mantle Cell Lymphoma (MCL)	280	China	clinicaltrials.gov
August 24, 2026	NCT07783100	Venetoclax, Chidamide, and Chiglitazar Sodium (VCC) in Patients With Relapsed/Refractory Acute Myeloid Leukemia	The First Affiliated Hospital of Xiamen University	Phase 2	Recruiting	Relapsed or Refractory Acute Myeloid Leukemia	30	China	clinicaltrials.gov
August 24, 2026	NCT07782164	Irreversible Electroporation (IRE) for Treating Recurrent Pelvic Tumors (PELFIRE Study)	Amsterdam UMC, location VUmc	Observational	Recruiting	Colorectal Carcinoma, Renal Cancer, Bladder Cancer, Cervical Cancer, Prostate Cancer, Ovarian Cancer, Lung Cancer...	27	Netherlands	clinicaltrials.gov
August 24, 2026	NCT07781891	RAPID: Phase 2 Platform Trial Of Promising Drugs For AYA Patients With R/R Ewing Sarcoma & DSRCT	M.D. Anderson Cancer Center	Phase 2	Not yet recruiting	Ewing Sarcoma	120	United States	clinicaltrials.gov
August 21, 2026	NCT07779798	A Phase 1, Open-Label, Dose-Escalation Study to Evaluate Safety, Tolerability, and Clinical Activity of CBX-663 in Participants With...	Crossbow Therapeutics, Inc.	Phase 1	Recruiting	Advanced Solid Tumors, Recurrent or Progressive Glioblastoma, Relapse or Refractory Myeloid Malignancies	120	United States	clinicaltrials.gov
August 21, 2026	NCT07779330	Maintenance Individualized Neuromodulation and Depression-detection Via Sensors for Early Treatment	National University Hospital, Singapore	Not applicable	Not yet recruiting	Depression Disorder	24	Singapore	clinicaltrials.gov
August 19, 2026	NCT07774533	68Ga-B7-H3 Nanobody ImmunoPET in Osteosarcoma	Peking University First Hospital	Early phase 1	Recruiting	Osteosarcoma, Osteosarcoma, Recurrent, Refractory	16	China	clinicaltrials.gov
August 19, 2026	NCT07773454	Study of Zanzalintinib in Children and Adolescents With Relapsed or Refractory Solid Tumors	Exelixis	Phase 1	Not yet recruiting	Cancer, Pediatric Cancer	18		clinicaltrials.gov
August 19, 2026	NCT07773285	Validation of the G8 Screening Tool for Prognostic Assessment of Frailty and Early Mortality in Elderly Individuals With Cancer...	Latin American Cooperative Oncology Group	Observational	Not yet recruiting	Solid Tumor, Metastatic Solid Tumor, Recurrent Solid Tumor	250	Brazil	clinicaltrials.gov
August 18, 2026	NCT07771803	A Pilot Study of Soursop Tea in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Multiple Myeloma (MM)	Roger Strair	Early phase 1	Recruiting	AML (Acute Myeloid Leukemia), Multiple Myeloma Refractory	20	United States	clinicaltrials.gov
August 18, 2026	NCT07771361	BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma and Multiple Myeloma	Luminary Therapeutics	Phase 2	Not yet recruiting	Non-Hodgkin Lymphoma Refractory/ Relapsed, Multiple Myeloma Refractory, Multiple Myeloma in Relapse, Non-Hodgkin...	90		clinicaltrials.gov
August 18, 2026	NCT07770698	A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia	BeOne Medicines	Phase 1/2	Not yet recruiting	Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, B-cell Acute Lymphoblastic Leukemia, Pediatric...	30		clinicaltrials.gov
August 14, 2026	NCT07766122	Analysis of the Performance of PSMA Emission Tomography in Patients With Prostate Cancer Treated With HIFU	University Hospital, Toulouse	Phase 4	Not yet recruiting	Prostate Cancer - Recurrent, Prostate Cancer (Diagnosis)	30	France	clinicaltrials.gov
August 14, 2026	NCT07765966	Phase 1 Dose Escalation Study of RXIM002 in Autoimmune Cytopenias	RiboX Therapeutics Ltd.	Phase 1	Not yet recruiting	Immune Thrombocytopenia (ITP)	27		clinicaltrials.gov
August 13, 2026	NCT07763938	CD19/CD20 Dual-Target in Vivo CAR-T Lentiviral Product in the Treatment of Relapsed/Refractory B-cell Malignancies	The First Affiliated Hospital with Nanjing Medical University	Phase 1	Not yet recruiting	Relapsed/Refractory B-cell Malignancies	80	China	clinicaltrials.gov
August 13, 2026	NCT07763496	Relacorilant and Nab-Paclitaxel in Recurrent or Metastatic Cervical Cancer	ARCAGY/ GINECO GROUP	Phase 2	Not yet recruiting	Recurrent or Metastatic Cervical Cancer	63	France	clinicaltrials.gov
August 13, 2026	NCT07763210	Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Therapy for Non Hodgkin Lymphoma	Vanderbilt-Ingram Cancer Center	Phase 2	Recruiting	Non-hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell...	59	United States	clinicaltrials.gov
August 7, 2026	NCT07751887	Middle Meningeal Artery Embolisation in Chronic Subdural Hematoma	University Hospital Hradec Kralove	Not applicable	Recruiting	Chronic Subdural Hematoma	200	Czechia	clinicaltrials.gov
August 5, 2026	NCT07748364	Glofitamab in B-NHL Using Mid-Therapy Intratumoral Transcriptomics	Joshua Brody	Phase 2	Not yet recruiting	Relapsed/Refractory Diffuse Large B-cell Lymphoma, Relapsed/Refractory Mantle Cell Lymphoma	16	United States	clinicaltrials.gov
August 4, 2026	NCT07744256	Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)	Beijing Biotech	Phase 1/2	Recruiting	Small Cell Lung Cancer (SCLC), Relapsed/Refractory SCLC, Extensive-stage SCLC	60	China	clinicaltrials.gov
August 3, 2026	NCT07743281	A Study of Treatment Patterns and Annualized Relapse Rate in Multiple Sclerosis Patients Who Escalate Versus Continue Disease-Modifying...	Novartis Pharmaceuticals	Observational	Completed	Multiple Sclerosis	753	United States	clinicaltrials.gov
August 3, 2026	NCT07741825	Mindfulness-based Relapse Prevention for Peer Workers	University of Texas at Austin	Not applicable	Recruiting	Relapse/Recurrence, Substance Use (Drugs, Alcohol), Burnout	80	United States	clinicaltrials.gov
July 31, 2026	NCT07738757	SKB264 Plus KL-A167 in MSI-H/dMMR Advanced Gynecological Malignancies	Peking Union Medical College Hospital	Phase 2	Not yet recruiting	Recurrent or Metastatic MSI-H/dMMR Gynecological Malignancies	80	China	clinicaltrials.gov
July 28, 2026	NCT07730619	To Explore the Influencing Factors and Solutions for Patients With Plaque Psoriasis Undergoing Relapse	First Affiliated Hospital Xi'an Jiaotong University	Observational	Active not recruiting	Plaque Psoriasis, Biologic Agents, Relapse, Influence Factors	140	China	clinicaltrials.gov
July 28, 2026	NCT07730125	Gene-edited T Regulatory Cells (CRG-150) for the Treatment of Relapsed/Refractory Malignancies	CoRegen, Inc.	Phase 1/2	Not yet recruiting	HR-positive, HER2-negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, Prostate Cancer	67		clinicaltrials.gov
July 27, 2026	NCT07728188	A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies...	AbbVie	Phase 3	Not yet recruiting	Relapsed or Refractory Multiple Myeloma	520	Australia, Canada, France, Germany, Hungary, Italy, Netherlands, Norway...	clinicaltrials.gov
July 27, 2026	NCT07727967	Oral Lactobacillus Crispatus Lc-G22 as Adjunctive Therapy for Vulvovaginal Candidiasis	BioGrowing Co., Ltd	Not applicable	Completed	Vulvovaginal Candidiasis	100	China	clinicaltrials.gov
July 24, 2026	NCT07725406	Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple Myeloma	Weill Medical College of Cornell University	Phase 1	Recruiting	Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed or Refractory Multiple Myeloma (MM)	32	United States	clinicaltrials.gov
July 23, 2026	NCT07723482	ML-016 in Advanced Cancer With Lung and/or Liver Involvement	BrYet US, Inc.	Phase 1/2	Recruiting	Advanced Solid Tumor With Lung and/or Liver Involvement	108	Australia	clinicaltrials.gov
July 23, 2026	NCT07723248	A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With...	ORIC Pharmaceuticals	Phase 3	Recruiting	Metastatic Castration Resistant Prostate Cancer	600	Puerto Rico, United States	clinicaltrials.gov
July 23, 2026	NCT07722312	S243249 Monotherapy in Patients With Relapsed or Refractory Acute Leukemia With a KMT2A or NUP98 Translocation or Relapsed or Refractory...	Servier	Phase 1/2	Not yet recruiting	Relapsed or Refractory Acute Leukemia, Relapsed or Refractory Acute Myeloid Leukemia	80		clinicaltrials.gov
July 23, 2026	NCT07722286	Relapse and Functional Outcomes in Anti-LGI1 Encephalitis	Shen Chun-Hong	Observational	Completed	Autoimmune Encephalitis, LGI1 Encephalitis, Limbic Encephalitis	112	China	clinicaltrials.gov
July 20, 2026	NCT07715630	In Vivo PICX CAR-T Therapy for R/R Multiple Myeloma	Chongqing Precision Biotech Co., Ltd	Phase 1	Recruiting	Relapsed or Refractory Multiple Myeloma (RRMM)	15	China	clinicaltrials.gov
July 20, 2026	NCT07713732	TLN-499 in Combination With Venetoclax in Patients With Relapsed/Refractory Solid Tumors	Treeline Biosciences, Inc.	Phase 1	Recruiting	Small Cell Lung Cancer ( SCLC ), Neuroendocrine Cancer, Malignant Pleural Mesotheliomas (Mpm), Synovial Sarcomas	120	Australia	clinicaltrials.gov
July 17, 2026	NCT07712562	A Phase 1/2 Study to Evaluate the Safety and Efficacy of Dibotatug (DR-01) in Adults With Bone Marrow Failure Syndromes	Dren Bio	Phase 1/2	Recruiting	Bone Marrow Failure Syndromes, Aplastic Anemias, Severe Aplastic Anemia (SAA), Severe Aplastic Anemia, Relapse, Severe...	60	United States	clinicaltrials.gov
July 17, 2026	NCT07711483	GLORY: Glofit-GemOx With Liso-Cel For Lymphoma	Massachusetts General Hospital	Phase 2	Recruiting	Lymphoma, B-cell Lymphomas, Relapsed/Refractory Large B-cell Lymphoma, Large B-cell Lymphoma	56	United States	clinicaltrials.gov
July 14, 2026	NCT07702851	A Study of Polatuzumab Vedotin and Glofitamab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Within 12 Months After...	Yonsei University	Phase 2	Not yet recruiting	Diffuse Large B-cell Lymphoma	47		clinicaltrials.gov
July 14, 2026	NCT07701772	LASER VERSUS CRYSTALLIZED PHENOL IN PILONIDAL SINUS DISEASE	Sanliurfa Education and Research Hospital	Not applicable	Recruiting	Sacrococcygeal Pilonidal Sinus Disease, Pilonidal Sinus Disease	120	Turkey (Türkiye)	clinicaltrials.gov
July 10, 2026	NCT07696481	Clinical Study on the Safety and Efficacy of PID23 Injection in Patients With Relapsed/Refractory Acute Leukemia	Zhujiang Hospital	Early phase 1	Not yet recruiting	Relapsed or Refractory Acute Leukemia, Relapsed or Refractory Acute Lymphoblastic Leukemia, Relapsed or Refractory...	18	China	clinicaltrials.gov
July 10, 2026	NCT07695896	Real-World Study of Bispecific Antibody in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma	Yanyan Liu	Observational	Not yet recruiting	Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma	200	China	clinicaltrials.gov
July 10, 2026	NCT07695740	Study of YKST02 in Adults With Relapsed or Refractory Multiple Myeloma	Excyte Biopharma Ltd	Phase 2	Not yet recruiting	Relapsed or Refractory Multiple Myeloma (RRMM)	64	China	clinicaltrials.gov
July 10, 2026	NCT07695532	A Clinical Risk Score to Stratify High-risk PanNETs	Fudan University	Observational	Completed	Pancreatic Neuroendocrine Tumors	552	China	clinicaltrials.gov
July 10, 2026	NCT07695012	CAR-T Cell Therapy for ALL	Dr. Zaineb Akram	Early phase 1	Recruiting	Relapsed Acute Lymphoblastic Leukemia (ALL)	10	Pakistan	clinicaltrials.gov
July 10, 2026	NCT07694674	Comparison of the Efficacy of Different Biologic Agents in Preventing Postoperative Endoscopic Recurrence of Crohn's Disease	Shanghai 10th People's Hospital	Observational	Recruiting	Inflamatory Bowel Disease, Crohn Disease (CD)	198	China	clinicaltrials.gov
July 8, 2026	NCT07689058	CAR-T in Relapsed/Refractory Multiple Myeloma	Dr. Zaineb Akram	Phase 2	Recruiting	Multiple Myeloma Refractory, Multiple Myeloma in Relapse	10	Pakistan	clinicaltrials.gov
July 7, 2026	NCT07686744	Neoantigen Peptide Vaccine Plus Pembrolizumab in Renal Cell Carcinoma	Jian Lin	Phase 1	Not yet recruiting	Renal Cell Carcinoma, Advanced, Recurrent, Refractory	8	China	clinicaltrials.gov
July 7, 2026	NCT07686588	Sacituzumab Tirumotecan Plus Immunotherapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma	Biying Chen	Phase 2	Not yet recruiting	Recurrent or Metastatic Head and Neck Carcinoma	20		clinicaltrials.gov
July 6, 2026	NCT07683195	Research on Early Recurrence of Locally Advanced Gastric Cancer Based on CT Radiomics Prediction	Liu Yang	Observational	Enrolling by invitation	Gastric Cancer	900	China	clinicaltrials.gov
July 6, 2026	NCT07682675	Study to Evaluate the Efficacy of Zanzalintinib in the Treatment of Relapsed or Metastatic Adenoid Cystic Carcinomas of the Head and Neck	UNICANCER	Phase 2	Not yet recruiting	Adenoid Cystic Carcinoma of the Salivary Gland, Recurrence, Metastatic Disease	51	France	clinicaltrials.gov
July 2, 2026	NCT07681596	A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma	AstraZeneca	Phase 1/2	Recruiting	Relapsed or Refractory Multiple Myeloma	101	Australia, United States	clinicaltrials.gov
June 29, 2026	NCT07672782	Tisotumab Vedotin in Squamous Cell Carcinoma of the Vulva	GOG Foundation	Phase 2	Not yet recruiting	Vulvar Carcinoma, Recurrent or Metastatic Vulvar Cancer, Squamous Cell Carcinoma Vulva	28	United States	clinicaltrials.gov
June 26, 2026	NCT07670260	GoFast CAR T-Cell Therapy for Recurrent Refractory B-Cell Lymphoma	Chinese PLA General Hospital	Early phase 1	Not yet recruiting	Relapsed or Refractory Large B-cell Lymphoma	9	China	clinicaltrials.gov
June 25, 2026	NCT07669194	Glofitamab Combined With Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma	Second Affiliated Hospital, Zhejiang University, School of Medicine	Observational	Not yet recruiting	Diffuse Large B-Cell Lymphoma (DLBCL)	30	China	clinicaltrials.gov
June 25, 2026	NCT07668557	Anti-CD33-CLL1 CAR-T Cells (ICG415) for the Treatment of Relapsed/Refractory Acute Myeloid Leukemia	iCell Gene Therapeutics	Phase 1	Recruiting	Acute Myeloid Leukemia (AML)	18	China	clinicaltrials.gov

Sponsors posting most

Sponsor	New trials	Latest
Institute of Hematology & Blood Diseases Hospital, China	11	May 13, 2026
Beijing Biotech	8	August 4, 2026
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	8	May 13, 2026
The First Affiliated Hospital of Soochow University	8	April 6, 2026
Fudan University	7	July 10, 2026
The First Affiliated Hospital with Nanjing Medical University	6	August 13, 2026
Sun Yat-sen University	6	June 3, 2026
Second Affiliated Hospital, Zhejiang University, School of Medicine	5	August 26, 2026
Tianjin Medical University Cancer Institute and Hospital	4	September 24, 2026
Chinese PLA General Hospital	4	September 16, 2026
Ruijin Hospital	4	May 29, 2026
Tongji Hospital	4	January 30, 2026
Memorial Sloan Kettering Cancer Center	4	October 7, 2025
Washington University School of Medicine	3	October 28, 2026
Massachusetts General Hospital	3	August 28, 2026
Jiangsu HengRui Medicine Co., Ltd.	3	August 27, 2026
Beijing InnoCare Pharma Tech Co., Ltd.	3	August 25, 2026
Treeline Biosciences, Inc.	3	July 20, 2026
AstraZeneca	3	July 2, 2026
Regeneron Pharmaceuticals	3	May 5, 2026

By phase

Phase	New trials	Latest
Phase 2	109	November 6, 2026
Phase 1	90	November 6, 2026
Observational	82	October 27, 2026
Not applicable	64	November 9, 2026
Phase 1/2	62	November 2, 2026
Early phase 1	30	August 19, 2026
Phase 3	25	September 16, 2026
Phase 2/3	10	August 28, 2026
Phase 4	10	August 14, 2026

By country

Country	New trials	Latest
China	186	November 6, 2026
United States	105	November 2, 2026
Italy	32	October 6, 2026
France	31	October 27, 2026
Spain	25	October 29, 2026
Australia	22	November 3, 2026
Canada	21	October 29, 2026
South Korea	15	April 13, 2026
Japan	14	May 27, 2026
Poland	12	October 8, 2026
Germany	12	September 25, 2026
Taiwan	11	July 27, 2026
United Kingdom	10	July 27, 2026
India	10	June 3, 2026
Turkey (Türkiye)	8	August 27, 2026
Netherlands	8	August 24, 2026
Brazil	8	August 19, 2026
Pakistan	7	October 26, 2026
Denmark	6	October 29, 2026
Czechia	6	August 7, 2026
Finland	6	May 27, 2026
Belgium	6	May 5, 2026
Greece	6	December 17, 2025
Egypt	5	November 9, 2026
Switzerland	5	September 25, 2026

Where the register publishes

U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Condition groups are the MeSH terms ClinicalTrials.gov assigns to each study's conditions; a study with several is in several groups. Sponsor class is the register's class of the lead sponsor. The central contact is in the full list only as the record prints it. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.